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in 24 455 patients showed that the rates of recur‑
rent VTE, fatal PE, and all ‑cause mortality were 
similar to the NOACs; however, the rate of major 
bleeding was significantly lower with the NOACs 
than with warfarin.2,4 Due to convenience in use 
and no need for routine monitoring, the num‑
ber of patients with VTE and atrial fibrillation 
(AF) who take NOACs increase worldwide. Re‑
cent data from the RIETE registry5 showed that 
a nonnegligible proportion of VTE patients re‑
ceived nonrecommended doses and regimens of 
NOACs, which was associated with a higher rate 
INTRODUCTION Venous thromboembolism 
(VTE), defined as deep vein thrombosis (DVT) 
or pulmonary embolism (PE), occurs in about 1 in 
1000 persons each year.1,2 There is evidence that 
VTE is often asymptomatic, underdiagnosed, and 
undertreated.3 For more than 60 years, vitamin 
K antagonists (VKAs) were the mainstay of VTE 
treatment. Non–vitamin K antagonist oral anti‑
coagulants (NOACs) have altered the landscape of 
treatment options. A meta ‑analysis of the 5 phase 
III trials comparing 4 NOACs (rivaroxaban, dab‑
igatran, apixaban, and edoxaban) with warfarin 
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ABSTRACT
INTRODUCTION The current awareness of venous thromboembolism (VTE) and knowledge of thrombo­
prophylaxis among patients receiving oral anticoagulation therapy (OAC) are insufficient.
OBJECTIVES We sought to develop and evaluate the usefulness of the Jessa AF Knowledge Question­
naire (JAKQ), modified for VTE patients.
PATIENTS AND METHODS Consecutive patients at least 1 month since the VTE event (n = 273, mean 
[SD] age, 51 [17] years; 52.7%, women; 55.9%, unprovoked event) were enrolled to the study.
RESULTS The median percentage of correct responses was 64.2% (interquartile range, 53%–73%; minimum, 
12%; maximum, 100%). Younger patients had better knowledge about VTE in general, including a higher 
proportion of correct responses to the question about the definition of PE (71.4% vs 57.7%, P = 0.03), 
about the possible consequence of DVT, including PE (81.1% vs 62%, P = 0.001) and VTE risk related to 
long travels (78.1% vs 59.2%, P = 0.002). There was no difference in overall scoring between patients 
taking new oral anticoagulants and those taking vitamin K antagonists (mean [SD], 64.1% [16.3%] vs 
63.9% [13.8%], respectively, P = 0.7). Regardless of the type of anticoagulants, 39.3% of patients knew 
that VTE is not always symptomatic, 33.6% knew what to do when they missed an OAC dose, and 50% 
did not know which painkillers are the safest in combination with anticoagulants. Education applied 
in 27 patients resulted in an increase in the median percentage of correct responses from 60% to 80% 
(P = 0.0001).
CONCLUSIONS Knowledge on VTE and anticoagulation is suboptimal among patients on VKA and NOACs. 
Education of VTE patients should be improved especially in older individuals on NOACs.
ORIGINAL ARTICLE Knowledge gaps in VTE 29
were anonymous and oral informed consent 
was obtained from each patient; the methods 
were performed in accordance with the relevant 
guidelines and regulations. Briefly, the JAKQ‑
‑VTE consisted of multiple ‑choice questions 
(4 answers) with only 1 correct answer. In each 
question, there was an “I do not know” option 
to avoid guessing. A correct answer was scored 
as 1 point, and an incorrect or “I do not know” 
answer, as 0 points. The questionnaires were 
collected by doctors who completed general in‑
formation about patients and medical data on 
the charts, which were then passed to an admin‑
istrative official in our hospital, who collected 
and inputted data into a computer, without be‑
ing aware of the aims of the survey. Data verifi‑
cation for their completeness was subsequently 
performed by another person. The final num‑
ber of patients who properly completed charts 
was 273. Two charts were excluded due to in‑
complete clinical data. A total score was calcu‑
lated from completed questions and displayed 
as a percentage.
The final version of the JAKQ ‑VTE was tested 
for sensitivity. A total of 27 VTE patients, who 
completed the JAKQ ‑VTE in July or August 2017, 
received education (20 ‑minute personal training 
with each patient) concerning the questions in‑
correctly answered. All responses were discussed 
with them by investigators. After 3 to 4 months, 
these patients were asked to complete the same 
questionnaire during the next ambulatory vis‑
it at our center.
Clinical data We documented clinical variables 
including concomitant diseases (ie, heart fail‑
ure, diabetes mellitus, inflammatory disease, 
vascular disease), risk factors for VTE and an‑
ticoagulant therapy with the dosing regimen. 
DVT and PE were diagnosed as described.13 
The diagnosis of DVT was established by a pos‑
itive finding in color duplex ultrasound (visu‑
alization of an intraluminal thrombus in calf, 
popliteal, femoral, or iliac veins). The diagno‑
sis of PE was based on the presence of char‑
acteristic symptoms and positive results of 
high ‑resolution spiral computed tomography. 
Patients who reported hormonal contracep‑
tion, pregnancy, childbirth, recent surgery or 
trauma, recent hospitalization, or long travel 
(>4 h), prior to the episode were classified as 
having provoked VTE. Active cancer was de‑
fined as newly diagnosed cancer, metastatic 
cancer, or cancer that was being treated and 
those individuals were analyzed separately. 
All the remaining patients were categorized 
as having unprovoked VTE. Prior major bleed‑
ing was defined as nonsurgical bleeding re‑
sulting in blood transfusion (at least 2 units 
of packed red blood cell units) or a significant 
fall in hemoglobin levels (at least 2 g/dl) or 
bleeding to critical organs, for example, intra‑
cranial bleeds.14 Minor bleedings on the cur‑
rent therapy as a potential factor enhancing 
of VTE recurrences, with no benefit in terms of 
bleeding or mortality.5
Although several risk factors and predictors 
of VTE recurrence have been identified, and 
effective VTE prophylaxis and treatment are 
available, knowledge about the disease among 
medical staff and patients seems to be insuffi‑
cient. Few articles have compared current un‑
derstanding of VTE,6-10 but all these studies ad‑
dressed mainly patients free of VTE.
Almodaimegh et al,6 who evaluated patients’ 
awareness of VTE and their perceptions of throm‑
boprophylaxis, using 18 closed ‑ended questions 
developed by combining 2 previously validated 
surveys,8,10 reported poor awareness of DVT and 
PE among hospitalized patients. Le Sage et al8 
demonstrated that one fifth of participants of 
their study had never heard of either DVT or 
PE. The findings from a global survey published 
by Wendelboe et al10 highlighted a relative lack 
of public awareness about thrombosis overall.
To our knowledge, there have been no studies 
designed to assess the awareness of the disease 
and anticoagulant therapy among VTE patients 
in relation to the medications used. We decided 
to modify the Jessa AF Knowledge Question‑
naire (JAKQ) containing 16 questions regarding 
issues relevant in patients with AF.11 This ques‑
tionnaire was introduced, validated, and tested 
by Desteghe and Heidbuchel.11 Its usefulness was 
also confirmed in a recent study on Polish pa‑
tients with AF,12 which showed that the knowl‑
edge of this arrhythmia and anticoagulation is 
better regarding the safety issues among subjects 
on NOACs compared with VKAs.
The aim of this study was to test patient’s 
knowledge about the VTE itself and its treat‑
ment with the use of the JAKQ ‑VTE and to de‑
termine the questionnaire’s usefulness in per‑
sonalized education among patients with VTE.
PATIENTS AND METHODS Patients We recruit‑
ed consecutive patients with documented VTE 
who were referred for further diagnostic work‑
up to the John Paul II Hospital in Kraków (Po‑
land), from July 2017 to January 2018. Eligible 
patients were older than 18 years of age, treated 
for at least a month with anticoagulants and able 
to provide consent. In the presence of the man‑
aging physicians, 275 patients with VTE were 
asked to complete the questionnaire.
Questionnaire The JAKQ, which was developed 
and validated to test the knowledge of patients 
with AF,11 was modified (JAKQ ‑VTE) by introduc‑
ing 8 new questions regarding VTE in the first 
and second sections (Supplementary material, 
Table S1). The modified questionnaire (JAKQ‑
‑VTE) also contained 16 questions. The choice 
of questions was discussed by investigators to 
reach consensus.
The study was approved by the Local Ethics 
Committee (by the Polish Chamber of Physi‑
cians and Dentist in Krakow). Questionnaires 
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A multivariate logistic regression analysis was 
conducted to determine predictors of correct 
responses to selected questions. The Wilcoxon 
test was applied to evaluate the effect of target‑
ed education. Backward logistic regression was 
applied. Statistical analyses were performed us‑
ing SPSS 23.0 (SPSS Inc., Chicago, Illinois, Unit‑
ed States). A P value of less than 0.05 was con‑
sidered significant.
RESULTS A total of 273 patients with VTE, 
mostly outpatients 265 (97.1%), were includ‑
ed in the final analysis (TABLE 1). The mean time 
interval since VTE diagnosis was 23 months. 
The  mean time interval since initiation of 
therapy was 10  months. There were 43  pa‑
tients (15.7%) treated with VKAs (30 [69.8%] 
on warfarin and 13 [30.2%] on acenocouma‑
rol) and 209 (76.5%) receiving NOACs. Among 
patients treated with NOACs, 119 (56.9%) re‑
ceived rivaroxaban. The less commonly used 
NOACs were dabigatran (n = 42 [20.0%]) and 
apixaban (n = 48 [22.9%]). Fifty ‑one individ‑
uals (24.4%) receiving NOACs were previous‑
ly treated with VKAs. As many as 19 patients 
(6.9%) received a low ‑molecular ‑weight heparin 
(LMWH) at therapeutic or intermediate doses 
for a mean of 9 months (range, 2–36 months).
Two patients did not receive any antithrom‑
botic treatment on the  day of completing 
the questionnaire. One was treated in the past 
with VKA and the other received LMWH.
Overall results and knowledge gaps revealed in 
the questionnaire The median percentage of 
correct responses was 64.2% (IQR, 53%–73%; 
minimum, 12%; maximum, 100% in 3 patients 
[1.09%]) (FIGURE 1). Time for participants to com‑
plete the questionnaire ranged between 3 to 
15 minutes (mean, 7 minutes) and showed a pos‑
itive correlation with age (r = 0.43, P <0.0001), 
but not with sex.
As shown in TABLE 2, most of the patients re‑
sponded correctly to the question about the def‑
inition of PE (67.8%), possible thrombotic con‑
sequences of DVT (76.1%), and about the VTE 
an interest in the disease and anticoagulation 
were also recorded.
Statistical analysis Continuous variables were 
presented as means (standard deviation) or medi‑
an (interquartile range) as appropriate. The Kol‑
mogorov–Smirnov test was used to determine 
the normal distribution of variables. Categori‑
cal variables were reported as a number and per‑
centage. The χ2 test was used to compare categor‑
ical variables. The analysis of variance or Krus‑
kal–Wallis tests for continuous variables were 
used to assess differences between the groups. 
TABLE 1 Characteristics of the study population
Parameter All patients (n = 273)
Age, y 51.0 (17.0)
Male sex, n (%) 129 (47.3)
Obesity, n (%) 105 (38.5)
Current smoking, n (%) 41 (15)
Thrombophilia, n (%) 70 (41.7)
Postthrombotic syndrome, n (%) 53 (19.4)
Active cancer, n (%) 21 (7.7)
Time interval since VTE diagnosis, mo 23 (9–51)
Time interval since initiating the OAC, mo 10 (5–22)
VTE characteristics, n (%)
Provoked VTE 118 (43.4)
Unprovoked VTE 152 (55.9)
Isolated DVT 122 (44.9)
Isolated PE 51 (18.8)
Recurrent VTE 102 (37.9)
OAC complications, n (%)
History of major bleeding 21 (7.7)
Easy bruising 42 (15.4)
Gingival bleeding 24 (8.8)
Heavy menstrual bleeding 33 (23.2)
Data are given as number (percentage), mean (SD), or median (interquartile range).
Abbreviations: DVT, deep vein thrombosis; OAC, oral anticoagulation; PE, pulmonary 
embolism; VTE, venous thromboembolism
Number of correct answers
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FIGURE 1 Frequency 
distribution of number 
of correct responses 
(in percentages) to 
16 questions
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into consideration only painkillers unprescribed 
by a physician. There was no difference in the per‑
centage of correct answers to this question be‑
tween patients with unprovoked and provoked 
VTE (52.7% vs 47.7%, P = 0.42).
There was no difference in the distribution of 
correct answers between men and women (mean, 
[SD] 66.6% [15.5%] vs 62.5% [16.3%], P = 0.81). 
There was no correlation between the treatment 
duration and the percentage of correct responses 
(r = 0.01, P = 0.81). A weak inverse correlation be‑
tween age and the percentage of correct respons‑
es was observed (r = –0.22, P = 0.003). Young‑
er patients had better knowledge about VTE in 
general, including a higher proportion of correct 
risk related to long travels (73.2%). There was also 
a fairly satisfactory knowledge about the impor‑
tance of a regular anticoagulant intake (83.3%), 
but uniformly poor about the duration of antico‑
agulant therapy (24.4%). A major adverse event of 
blood thinners, that is, an increased risk of bleed‑
ing, was obvious to 91.9% of the respondents. 
However, only 39.3% of patients knew that VTE 
is not always symptomatic. Half of all patients 
(50.4%) were aware that blood thinners prevent 
the recurrence of VTE and only one third (33.6%) 
knew what to do when they missed a dose. Of 
note, half of the patients did not know which 
painkillers are the safest in combination with 
anticoagulants. Patients were informed to take 
TABLE 2 Specific topics addressed in the JAKQ ­VTE with the percentage of correct responses among patients with venous thromboembolism in 2 
age groups
Parameter All (n = 273) Patients <65 years 
(n = 202)
Patients ≥65 years 
(n = 71)
P value
8 questions about VTE in general
PE occurs when pulmonary arteries are partially occluded, most 
often by clots.
183 (67.8) 142 (71.4) 41 (57.7) 0.03
VTE is not always accompanied by pain or edema of the limb. 107 (39.3) 78 (38.8) 29 (40.8) 0.76
Venous ultrasound should be performed to detect DVT. 144 (52.9) 107 (53.2) 37 (52.1) 0.87
DVT can lead to PE. 207 (76.1) 163 (81.1) 44 (62.0) 0.001
Blood thinners prevent the recurrence of the disease. 137 (50.4) 100 (49.3) 38 (53.5) 0.54
Travel by air or car for more than 6–8 hours increases the risk of VTE. 199 (73.2) 157 (78.1) 42 (59.2) 0.002
Being overweight increases the risk of VTE. 201 (74.2) 154 (76.6) 47 (67.1) 0.11
Blood thinners should be used always, for at least 3 months after 
diagnosis of VTE.
66 (24.4) 51 (25.5) 15 (21.4) 0.49
5 questions about OAC therapy
Patients with VTE should always take their blood thinners, 
especially if VTE is unprovoked.
214 (83.3) 159 (84.1) 55 (80.9) 0.53
Possible side effects of blood thinners are the occurrence of 
bleedings and longer bleeding times in case of injuries.
238 (91.9) 177 (93.2) 61 (88.4) 0.21
VTE patients may only take painkillers based on paracetamol. 130 (50.6) 98 (51.9) 32 (47.1) 0.49
When VTE patients regularly have minor nose bleeds (that 
spontaneously cease), they should contact the general 
practitioner or specialist, while continuing to take their blood 
thinner.
168 (64.9) 130 (68.4) 38 (55.1) 0.04
If a VTE patient needs an operation, he/she should consult a doctor 
to discuss possible options.
167 (66.8) 120 (65.6) 47 (70.1) 0.49
3 questions about VKA
VTE patients taking VKA should have their blood thinning checked 
at least once a month.
95 (86.4) 68 (85.0) 27 (90.0) 0.75
When VTE patients taking VKA have forgotten to take their blood 
thinner, they should still take their forgotten pill (immediately or 
at the next dose).
37 (33.6) 26 (32.5) 11 (36.7) 0.68
INR is a measure to check how thick or how thin the blood is. 91 (82.7) 64 (80.0) 27 (90.0) 0.21
3 questions about NOAC
For patients taking NOAC, it is important to take their blood thinner 
at the same time every day.
– 145 (91.2) 48 (85.7) 0.24
When VTE patients taking NOAC have forgotten to take their blood 
thinner, they can still take that dose, unless the time till the next 
dose is less than the time after the missed dose.
– 90 (57.0) 29 (51.8) 0.50
The NOAC card should be shown to their general practitioner and 
specialist by VTE patients.
– – – –
Data are presented as number (percentage) of patients. 
Abbreviations: INR, international normalized ratio; others, see TABLE 1
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alone (mean [SD], 64.6% [15.6%] vs 63.0% [16.4%], 
P = 0.24) and for 118 patients (43.4%) with pro‑
voked VTE and 152 individuals (55.9%) with un‑
provoked VTE (mean [SD], 62.5% [16.8%] vs 66.6% 
[15.2%], P = 0.27).
VTE patients on NOACs versus those on VKAs 
had similar demographic characteristics, VTE 
type, and risk factors. There was no difference in 
overall scoring between NOAC and VKA patients 
(mean [SD], 64.1% [16.3%] vs 63.9% [13.8%], P = 
0.7), and there was no difference in the distribu‑
tion of correct answers (Supplementary materi‑
al, Table S3).
Regarding the question what to do when they 
missed an OAC dose, as few as 28.6% of patients 
on VKA knew the correct response. A similar 
question regarding the missed OAC dose was 
answered correctly by 56.4% of the NOAC us‑
ers. Patients receiving heparins did not differ in 
responses to the question about the definition 
of PE (71.4% vs 57.7%, P = 0.03), about possi‑
ble consequence of DVT, including PE (81.1% vs 
62%, P = 0.001) and VTE risk related to long trav‑
els (78.1% vs 59.2%, P = 0.002, TABLE 2).
There was no difference in overall scoring on 
JAKQ ‑VTE between 76 (27.8%) patients treated 
up to 6 months and 197 (72.2%) treated for more 
than 6 months (mean, [SD] 63.3% [16.9%] vs 
62.9% [14.7%], P = 0.8), although the latter sub‑
group had better knowledge about the necessity 
of long ‑term anticoagulation (86.2% vs 75%, P = 
0.03; Supplementary material, Table S2).
There was no difference in overall scoring on 
JAKQ ‑VTE between 102 individuals (37.9%) with 
recurrent VTE and 166 (60.8%) with the first epi‑
sode of VTE (mean [SD], 63.6% [15.3%] vs 63.9% 
[16.1%], P = 0.4). The same was observed for 151 pa‑
tients (55.5%) with PE and 121 (44.5%) with DVT 
TABLE 3 Comparison of the percentage of correct responses among 27 patients with venous thromboembolism before and at 3 to 4 months after 
educational intervention
Parameter T1 T2 P value
8 questions about VTE in general
PE occurs when pulmonary arteries are partially occluded, most often by clots. 16 (59.2) 26 (96.3) 0.004
VTE is not always accompanied by pain or edema of the limb. 10 (37.0) 18 (66.6) 0.06
Venous ultrasound should be performed to detect DVT. 14 (51.8) 17 (62.9) 0.54
DVT can lead to PE. 21 (77.7) 23 (85.1) 0.61
Blood thinners prevent the recurrence of the disease. 13 (48.1) 21 (77.8) 0.009
Travel by air or car for more than 6–8 hours increase the risk of VTE. 20 (74.0) 22 (81.4) 0.72
Being overweight increases the risk of VTE. 25 (92.5) 24 (88.8) 1.00
Blood thinners should be used always, for at least 3 months after diagnosis of VTE. 4 (14.8) 3 (11.1) 1.00
5 questions about OAC therapy
Patients with VTE should always take their blood thinners, especially if VTE is unprovoked. 17 (68.0) 23 (92.0) 0.07
Possible side effects of blood thinners are the occurrence of bleedings and longer bleeding 
times in case of injuries.
25 (96.1) 24 (92.3) 1.00
VTE patients may only take painkillers based on paracetamol. 10 (38.4) 23 (88.4) 0.003
When VTE patients regularly have minor nose bleeds (that spontaneously cease), they 
should contact the general practitioner or specialist, while continuing to take their blood 
thinner.
17 (65.3) 22 (84.6) 0.22
If a VTE patient needs an operation, he/she should consult a doctor to discuss possible 
options.
13 (56.5) 17 (73.9) 0.42
3 questions about VKAa
VTE patients taking VKA should have their blood thinning checked at least once a month. 7 (87.5) 8 (100) –
When VTE patients taking VKA have forgotten to take their blood thinner, they should still 
take their forgotten pill (immediately or at the next dose).
1 (12.5) 1 (12.5) –
INR is a measure to check how thick or how thin the blood is. 8 (100) 8 (100) –
3 questions about NOACb
For patients taking NOAC, it is important to take their blood thinner at the same time every 
day.
20 (86.9) 20 (86.9) 0.47
When VTE patients taking NOAC have forgotten to take their blood thinner, they can still 
take that dose, unless the time till the next dose is less than the time after the missed 
dose.
10 (43.4) 18 (78.2) 0.02
The NOAC card should be shown to their general practitioner and specialist by VTE patients. 1 (4.34) 7 (30.4) –
Data are presented as number (percentage) of patients. 
a Refers to 3 patients still on VKAs and 5 previously treated with these agents, who were on NOACs while completing the questionnaire.
b Refers to 23 patients.
Abbreviations: T1, test at baseline; T2, test after 3–4 months; others, see TABLE 1
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of correct responses about the essence of the dis‑
ease in other studies that evaluated the knowl‑
edge about VTE was lower,6,8,10 but all these stud‑
ies addressed mainly patients free of VTE. Al‑
modaimegh et al6 and Le Sage et al8 conducted 
their study among hospitalized patients, with 
14.4% and 14.6% of patients with personal his‑
tory of VTE, respectively, while Wendelboe et 
al10 evaluated the global awareness of thrombo‑
sis in various countries, independent of person‑
al history of VTE. 
This study is the first to assess the knowledge 
and the effects of the education in the group of 
patients following VTE receiving the current 
types of anticoagulant medications. With the NO‑
ACs market growing, it is necessary to consid‑
er the specificity of this class of oral anticoagu‑
lants in the education of VTE patients, including, 
among others, the dosing regimen (once or twice 
daily) or the principles of discontinuation in var‑
ious clinical situations. We found that therapy 
with rivaroxaban, dabigatran, or apixaban among 
VTE patients, though it appears easier in every‑
day use, was not associated with better knowl‑
edge of the disease and treatment compared with 
current VKA users despite a significantly longer 
treatment time. 
In the present study, there was no association 
between treatment duration and the knowledge 
of the disease or anticoagulation. Overall, the re‑
sults revealed that awareness of VTE is subopti‑
mal in subjects who experienced such events. A 
comparison of our recent study on AF patients12 
and the current VTE study indicates that in 
the former, most patients responded correctly 
to the question about the definition of the dis‑
ease as well as possible thrombotic complications 
of arrhythmia and VTE. There was also a good 
knowledge about the time interval for interna‑
tional normalized ratio (INR) control and the def‑
inition of INR. 
their knowledge on the disease from the remain‑
der (data not shown).
Effect of education Twenty ‑seven patients re‑
ceiving OAC (mean [SD] age, 47.8 [15.3] years, 
including 23 [85.2%] using NOACs, 3 [11.1%] on 
VKAs, and 1 [3.7%] using LMWH) were asked to 
complete the questionnaire again after the edu‑
cational intervention (TABLE 3). This subgroup did 
not differ from the remaining patients in terms 
of basic characteristics (data not shown).
The median percentage of correct respons‑
es was 60 (minimum, 40%; maximum, 86.7%) 
at baseline and 80 (minimum 60% and maxi‑
mum 100%) at 3 to 4 months after the training 
(FIGURE 2). The analysis of individual questions af‑
ter the educational intervention showed that pa‑
tients had better knowledge about the definition 
of PE (59.2% vs 96.3%, P = 0.004), about the saf‑
est painkiller in combination with OAC thera‑
py (38.4% vs 88.4%, P = 0.003), and what to do 
when they missed a NOAC dose (47.6% vs 85.7%, 
P = 0.02, TABLE 3).
DISCUSSION The  present study evaluat‑
ed the  usefulness of a  JAKQ ‑VTE in testing 
the knowledge of patients with VTE. This mod‑
ification of the JAKQ, compared with the previ‑
ous surveys that analyzed the understanding of 
the disease and VTE risk factors in various patient 
groups,6-10 enables an evaluation of the awareness 
of the safe therapy principles in subjects who ex‑
perienced VTE and received anticoagulant agents 
including NOACs.
The JAKQ ‑VTE can be completed within a few 
minutes and can be widely used in the outpatient 
setting. This study demonstrates a satisfactory 
awareness about the definition of PE, possible 
thrombotic consequences of DVT, and about se‑
lected risk factors among patients who experi‑
enced VTE a few months earlier. The proportion 
FIGURE 2 Percentage 
of correct responses 
at baseline and at 3 to 
4 months after 
the training (P = 0.0001)
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is recommended. Our study indicates that older 
VTE patients on NOACs have statistically lower 
scores using the JAKQ ‑VTE compared with young‑
er, including safety ‑related questions, which high‑
lights the need for elderly dedicated education‑
al programs. The optimal approach to improve 
knowledge in this growing group in aging soci‑
ety remains to be established.
Various methods are sought to determine and 
improve the knowledge level about AF but there 
are insufficient data for VTE patients. We dem‑
onstrated that JAKQ ‑VTE seems to be a good 
tool to efficiently guide and target personalized 
education in VTE patients. Discussing the re‑
sults of the questionnaire with the patient and 
indicating the correct answers is a form of tar‑
geted education. In the group of the retested pa‑
tients, we observed that education substantial‑
ly improved their knowledge about the defini‑
tion of PE, about the safest painkiller in combi‑
nation with OAC therapy and what to do when 
they missed a NOAC dose, which are important 
questions regarding the efficacy and safety of an‑
ticoagulation in VTE like in AF.
It should be highlighted that like among AF pa‑
tients,11,12 there is a low use of cards containing 
information for patients on anticoagulation. It 
is of importance that specialists dealing with pa‑
tients on anticoagulation require access to tools, 
potentially including specific software, to guide 
systematic patient assessment and workflow.26
The study has several limitations. First, its 
small sample size requires validation in a larg‑
er group in other countries. The study was con‑
ducted at a hospital dealing with cardiovascular 
diseases with well ‑organized clinics for outpa‑
tients with thrombotic diseases and OAC compli‑
cations; therefore, our results could not be easily 
translated to primary care or local smaller hospi‑
tals. The score on the JAKQ ‑VTE may depend on 
the level of educational efforts at the time of di‑
agnosis and initiation of therapy, which has not 
been addressed in this study. For 2 years our hos‑
pital has been distributing information booklets 
pertaining to OAC along with discharge cards.
We did not analyze the effect of the patients’ 
level of education or cognitive function on VTE‑
‑related knowledge. VTE patients still receiving 
VKAs were underrepresented (15.7% of the whole 
group), so the data for them should be interpret‑
ed with caution; however, this low proportion re‑
flects current trends in most European countries 
with regard to preferred anticoagulants.
Conclusions There are still important knowl‑
edge gaps concerning VTE in general and the as‑
sociated oral anticoagulation therapy. The cur‑
rent study indicates that the JAKQ ‑VTE could 
be a useful tool in everyday practice to efficiently 
guide and target personalized education in VTE 
patients. The modified questionnaire present‑
ed in this study could help identify the VTE pa‑
tients on which education should focus. Irrespec‑
tive of the type of OAC therapy, education of VTE 
In both studies, we found the same knowledge 
gaps. As few as about 1 in 4 of VKA patients knew 
what to do when they missed an OAC dose. A sim‑
ilar question regarding a missed OAC dose was an‑
swered correctly by half of the NOAC users. Thus, 
we conclude that the knowledge of the therapy 
safety does not depend on the disease type, but 
on the therapy type. Because of the higher price 
of NOACs, doctors devote more time to present 
the advantages and disadvantages of this therapy.
Looking for factors affecting the percentage of 
correct responses, we found that the group fol‑
lowing unprovoked VTE, which has recommen‑
dations to use anticoagulation on a long ‑term ba‑
sis,15 scored similarly to those with provoked ep‑
isodes, which might have practical implications 
in terms of an increased risk of treatment fail‑
ure and bleedings. However, we observed that 
patients treated for 6 months or longer had bet‑
ter knowledge about the necessity of long ‑term 
drug intake, which suggests that patients largely 
accepted this therapy although it had a potential‑
ly strong impact on their everyday lives.
The use of various anticoagulants in our study 
is similar to real ‑life data showing a large pro‑
portion of VTE patients receiving NOACs2,16-19; 
however, in Poland we found a relatively high‑
er proportion of VTE patients receiving dabiga‑
tran (20%). Among the participants of the RIE‑
TE registry5 including the clinical characteristics, 
treatment patterns, and outcomes in patients di‑
agnosed with VTE, only 2% obtained dabigatran 
for a long ‑term therapy. In the Danish Nation‑
wide Study,20 which investigated temporal trends 
in initiation of rivaroxaban or apixaban or dab‑
igatran vs VKA in patients with VTE, only 0.5% 
received dabigatran vs 38.7% treated with rivar‑
oxaban and 5.4% using apixaban. Similar to this 
study, Badreldin et al21 reported in a cohort of 
VTE patients that only 2% of patients initiated 
dabigatran compared with 53%, 40%, and 5% ini‑
tiated on rivaroxaban, apixaban, and edoxaban, 
respectively. The use of rivaroxaban versus apix‑
aban or dabigatran did not affect the proportion 
of patients who responded well to the questions. 
Regardless of the type of a NOAC, we observed 
good knowledge about the importance of a regu‑
lar anticoagulant but poor about the duration of 
anticoagulant therapy. Poor knowledge in both 
treatment groups was observed in one particu‑
lar question concerning what to do with a missed 
OAC dose, which is of key importance for the effi‑
cacy of anticoagulants, in particular NOACs. Our 
findings suggest that a wide use of NOACs in VTE 
patients has not improved the VTE awareness yet.
Importantly, we observed an inverse corre‑
lation between age and the percentage of cor‑
rect responses. Since several investigators re‑
ported a higher risk for total DVT and PE (up to 
6 times higher) in elderly patients compared with 
younger subjects22,23 and age increases the risk of 
bleeding related to anticoagulant treatment,22,24,25 
educational efforts should be focused on this 
group, especially if a long ‑term anticoagulation 
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patients should be improved with a particular em‑
phasis on elderly population treated with NOACs.
SUPPLEMENTARY MATERIAL Supplementary ma‑
terial is available with the main article at www.
pamw.pl.
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